GlassScriptPhysician profile
Waverly Peakes
NPI 1831108414
$2,700.66
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $334 · 2021: $543 · 2022: $860 · 2023: $531 · 2024: $75.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $603.13 | 2019-2023 | |
| Abbvie INC. | $330.71 | 2019-2022 | |
| Daiichi Sankyo INC. | $211.04 | 2019-2023 | Injectafer |
| Therapeuticsmd, INC. | $185.40 | 2019-2022 | |
| Astellas Pharma US INC | $175.19 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $150.57 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $140.55 | 2021-2022 | |
| Scynexis, INC. | $113.13 | 2021-2022 | |
| Pfizer INC. | $109.41 | 2019-2022 | |
| Organon LLC | $91.95 | 2021-2024 | Nexplanon |
| Avion Pharmaceuticals | $68.93 | 2019-2020 | |
| Exeltis, USA INC. | $62.49 | 2021-2023 | Slynd |
| Allergan, INC. | $60.34 | 2019 | |
| Hologic Sales and Service, LLC | $52.40 | 2022-2023 | Affirm Prone Biopsy System |
| Merck Sharp & Dohme LLC | $41.40 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $39.35 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $32.43 | 2019 | |
| Sumitomo Pharma America, INC. | $30.83 | 2023 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $22.82 | 2021 | |
| Abbott Laboratories | $21.82 | 2022 | |
| Lupin INC. | $19.73 | 2020 | |
| Ascend Therapeutics US, LLC | $18.18 | 2022 | |
| Heron Therapeutics, INC. | $17.58 | 2024 | Zynrelef |
| Vertical Pharmaceuticals, LLC | $16.11 | 2019 | |
| Evofem Biosciences, INC. | $15.23 | 2022 | |
| Novo Nordisk INC | $13.02 | 2019 | |
| Ethicon US, LLC | $12.64 | 2021 | |
| Sage Therapeutics, LLC | $12.63 | 2020 | |
| Medtronic, INC. | $12.12 | 2022 | |
| Amgen INC. | $11.33 | 2019 | |
| Meditrina | $8.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waverly Peakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.